- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2055-0936
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era ; volume:2 ; number:1 ; day:27 ; month:9 ; year:2016 ; pages:1-7 ; date:12.2016
Tropical diseases, travel medicine and vaccines ; 2, Heft 1 (27.9.2016), 1-7, 12.2016
- Creator
-
Stevenson, Heather L.
- Contributor
-
Utay, Netanya S.
SpringerLink (Online service)
- DOI
-
10.1186/s40794-016-0038-5
- URN
-
urn:nbn:de:1111-2016102911153
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Stevenson, Heather L.
- Utay, Netanya S.
- SpringerLink (Online service)
Other Objects (12)
HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination
Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy
Direct-acting antiviral therapy may help restore HCV-induced impaired redox balance and liver fibrosis process
Effect of direct-acting antiviral drugs on portal circulation hemodynamics in cirrhotic patients infected with HCV
Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices
Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use
HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients
Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
Role of abbreviated MRI protocol for screening of HCC in HCV related cirrhotic patients prior to direct-acting antiviral treatment
Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy
HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination
Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy
Direct-acting antiviral therapy may help restore HCV-induced impaired redox balance and liver fibrosis process
Effect of direct-acting antiviral drugs on portal circulation hemodynamics in cirrhotic patients infected with HCV
Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices
Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use
HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients
Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
Role of abbreviated MRI protocol for screening of HCC in HCV related cirrhotic patients prior to direct-acting antiviral treatment
Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy
HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination
Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy
Direct-acting antiviral therapy may help restore HCV-induced impaired redox balance and liver fibrosis process
Effect of direct-acting antiviral drugs on portal circulation hemodynamics in cirrhotic patients infected with HCV
Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices
Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use
HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients
Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
Role of abbreviated MRI protocol for screening of HCC in HCV related cirrhotic patients prior to direct-acting antiviral treatment